This competitive landscape analysis was generated using AI-powered research workflows in Eureka LS, which integrates patent data, literature, and molecular insights into a structured report in minutes.
Here is a comprehensive competitive landscape report for Ulcerative Colitis (UC), synthesized from 480+ drugs in development, 74 active Phase 3 trials, deal intelligence, clinical guidelines, and translational research data.
Executive Summary
Ulcerative Colitis is one of the most commercially active inflammatory bowel disease (IBD) indications globally, with 480+ drugs in development and 137 approved agents across multiple drug classes. The landscape has undergone a structural transformation over the past five years, shifting from TNF-α inhibitor dominance to a multi-mechanism paradigm encompassing IL-23 inhibitors, JAK inhibitors, and S1P receptor modulators. AbbVie retains the broadest portfolio with two approved blockbusters (upadacitinib + risankizumab), while Eli Lilly, Pfizer/Arena, Gilead, and J&J (Janssen) compete across overlapping mechanisms. The pipeline is notably crowded at Phase 3 with 27 active Phase 3 assets, including emerging TL1A-targeted bispecifics, oral IL-23 receptor antagonists, and next-generation integrin modulators — pointing toward both intensifying competition and significant remaining unmet needs in biologic-refractory patients.
Traditionally, compiling this level of analysis would require weeks of manual research across platforms like Google Patents and PubMed. With Eureka LS, the same process can be automated—from extracting molecules to mapping competitive pipelines—into a structured output like the report below.
1. Disease Overview & Pathophysiology
UC is a chronic, relapsing-remitting inflammatory disorder predominantly confined to the colonic mucosa, presenting with diarrhea, rectal bleeding, mucus passage, and abdominal pain.
Key molecular drivers:
- Mucosal immune dysregulation: Th1/Th17 axis overactivation, elevated TNF-α, IL-6, IL-12, IL-23, and IL-33
- Epithelial barrier dysfunction: Disrupted tight junctions, goblet cell loss, increased intestinal permeability
- JAK-STAT signaling: Aberrant JAK1/JAK2/TYK2 activation driving cytokine amplification
- Gut microbiome dysbiosis: Reduced microbial diversity, loss of butyrate-producing bacteria
- S1P receptor dysregulation: Lymphocyte trafficking to inflamed mucosa
Active translational research focuses on Tim-4 expression in UC-associated immune infiltration, JAK2/STAT3 and NF-κB pathway modulation, and transcriptomic profiling of dysregulated gene networks.
Disease burden: Bowel urgency is a key symptom affecting quality of life even in clinical remission — moderate-to-severe urgency reported in ~1 in 25 remission events, strongly correlated with disability (IBD Disk) and depression (PHQ-9).
2. Standard of Care (SoC) & Treatment Algorithm
Per ACG 2025 Clinical Guideline Update and NICE NG130:
| Line | Severity | Therapy |
|---|---|---|
| 1st line | Mild–moderate | Oral/topical aminosalicylates (5-ASA/mesalamine); budesonide MMX |
| 2nd line | Moderate–severe (inadequate 5-ASA response) | Corticosteroids (induction); thiopurines (azathioprine/6-MP) for maintenance |
| 3rd line / Advanced | Moderate–severe, steroid-dependent/refractory | Biologics (anti-TNF, anti-integrin, anti-IL-23) or JAK inhibitors or S1P modulators |
| Rescue / Refractory | Acute severe, steroid-refractory | IV cyclosporine, infliximab, or colectomy |
Key trend: Guidelines increasingly support early advanced therapy (“treat-to-target”) with histological remission as an emerging endpoint, alongside traditional clinical and endoscopic remission.
Generate Competitive Landscape Reports Like This — in Minutes
Powered by Eureka LS AI
- ✔ Analyze patents, literature, and pipelines together
- ✔ Extract molecule & SAR data automatically
- ✔ Compare competitors and identify key assets
- ✔ Get structured reports instantly
3. Approved Drug Landscape — Competitive Tiers
Tier 1: Market Leaders (Approved, High Revenue Potential)
| Drug | Mechanism | Originator/Active Org | Approval Date | Drug Type |
|---|---|---|---|---|
| Upadacitinib (Rinvoq) | JAK1 inhibitor | AbbVie | Aug 2019 | Small molecule |
| Risankizumab (Skyrizi) | IL-23p19 inhibitor | AbbVie | Mar 2019 | Monoclonal antibody |
| Mirikizumab (Omvoh) | IL-23p19 inhibitor | Eli Lilly | Mar 2023 | Monoclonal antibody |
| Etrasimod (Velsipity) | S1PR1/4/5 agonist | Arena/Pfizer | Oct 2023 | Small molecule |
| Ozanimod (Zeposia) | S1PR1/5 modulator | Celgene/BMS | Mar 2020 | Small molecule |
| Filgotinib (Jyseleca) | JAK1 inhibitor | Gilead | Sep 2020 | Small molecule |
Tier 2: Recent Approvals (2024–2026)
| Drug | Mechanism | Approval Date | Notes |
|---|---|---|---|
| Icotrokinra | IL-23R inhibitor (cyclic peptide) | Mar 2026 | J&J; first oral IL-23R antagonist for UC |
| Bewintinib | JAK2 inhibitor | Apr 2026 | Hangzhou Guangliang; China-originated |
| Sitokiren Malate | Small molecule | Dec 2025 | — |
| Picankibart | Monoclonal antibody | Nov 2025 | China-originated |
| Mufemilast | Small molecule | Sep 2025 | — |
| Ebdarokimab | Monoclonal antibody | Apr 2025 | — |
| Ivarmacitinib | Small molecule | Mar 2025 | China-originated JAK inhibitor |
Legacy Approved Agents (Foundational)
Anti-TNFs (infliximab, adalimumab, golimumab) and anti-integrin vedolizumab remain widely used first-line biologics. Biosimilar competition for adalimumab is intensifying — multiple active commercial deals (Boehringer Ingelheim, Alvotech, Meitheal) expand access.
4. Competitive Arena Map
5. Phase 3 Pipeline — Active Competitive Battleground
27 drugs currently at Phase 3 in UC. Key assets:
| Drug | Mechanism | Sponsor | Trial Status | Key Trial |
|---|---|---|---|---|
| Duvakitug | Anti-TL1A mAb | Roche/Prometheus | Recruiting | SUNSCAPE-1/2 |
| Afimkibart (RO7790121) | Anti-IL-34/CSF-1R? mAb | Roche | Recruiting | AMETRINE-1/2 |
| Icotrokinra | IL-23R cyclic peptide | J&J | Recruiting | ICONIC-UC |
| Obefazimod | RNA splicing modulator | Abivax | Phase 3 | — |
| Tulisokibart | Anti-TL1A mAb | Prometheus/Roivant | Phase 3 | — |
| Girocitinib | JAK inhibitor | — | Phase 3 | — |
| Zasocitinib | TYK2 inhibitor | — | Phase 3 | — |
| Vidofludimus calcium | DHODH inhibitor | Immunic | Phase 3 | — |
| Lutikizumab | IL-1α/β bispecific | AbbVie | Phase 3 | — |
| Mocravimod HCl | S1P modulator | Gossamer Bio | Phase 3 | — |
| Risankizumab vs Vedolizumab | Head-to-head | AbbVie | Recruiting | REVAMP |
| Mirikizumab + Tirzepatide | IL-23i + GLP-1/GIP | Eli Lilly | Recruiting | COMMIT-UC |
Notable emerging signals:
- TL1A has become the hottest new target — Roche/Prometheus (duvakitug, SUNSCAPE-1/2) and Roivant/Prometheus (tulisokibart) are both in Phase 3
- Oral IL-23R antagonism (icotrokinra) represents a novel modality beyond injectable biologics
- Combination biology (mirikizumab + tirzepatide) tests obesity-IBD comorbidity hypothesis
- Pediatric expansion: Risankizumab (MIGHTY), filgotinib (Galapeduca), guselkumab (TRILOGY) all recruiting in pediatric UC
6. Mechanism Route Differentiation Matrix
| Player | Anti-TNF | Anti-Integrin | IL-23i | JAKi | S1PR | TL1A | IL-23R oral |
|---|---|---|---|---|---|---|---|
| AbbVie | Strong (legacy) | — | Strong (risa) | Strong (upa) | — | Moderate (lutikizumab IL-1) | — |
| Eli Lilly | — | — | Strong (miri) | — | — | — | — |
| J&J (Janssen) | Strong (infliximab/golimumab) | Strong (vedolizumab) | — | — | — | — | Strong (icotrokinra) |
| Pfizer | — | — | — | — | Strong (etrasimod) | Moderate (TL1A bispecific option) | — |
| Gilead | — | — | — | Strong (filgotinib) | — | — | — |
| Roche/Chugai | — | — | — | — | — | Strong (duvakitug) | — |
| BMS/Celgene | — | — | — | — | Strong (ozanimod) | — | — |
| Prometheus/Roivant | — | — | — | — | — | Strong (tulisokibart) | — |
7. Deal Intelligence (2021–2025)
| Deal | Type | Value | Status |
|---|---|---|---|
| AbbVie acquires Landos Biopharma (omilancor/LANCL) | M&A | $212M total ($137M upfront + $75M milestones) | Completed Mar 2024 |
| Roche option on Pfizer TL1A bispecific (p40/TL1A) | Option/Collaboration | Undisclosed | Active |
| Chugai in-licenses RG6631 (anti-TL1A) from Roche | License | Undisclosed | Active Aug 2024 |
| EA Pharma → Ensho Therapeutics (EA1080, oral α4β7 antagonist) | License | Undisclosed | Active Jun 2024 |
| NImmune Biopharma acquires omilancor Asia rights | Asset acquisition | Undisclosed | Active Oct 2024 |
| Equillium/Ono — itolizumab (anti-CD6) | Collaboration | $164.5M (terminated) | Terminated |
Deal intelligence synthesis:
- TL1A is the most deal-active new target in UC, attracting Roche, Pfizer, and Chugai
- AbbVie’s acquisition of Landos expands its UC portfolio into LANCL agonists (novel innate immune pathway)
- Biosimilar commercialization deals (adalimumab, vedolizumab) reflect the maturing anti-TNF/integrin segment
- Oral small-molecule integrin antagonism (EA1080) signals continued interest in gut-selective, orally dosed mechanisms
8. Unmet Needs & Competitive White Spaces
| Unmet Need | Current Gap | Pipeline Response |
|---|---|---|
| Biologic-refractory patients | ~30–40% fail all advanced therapies | TL1A antagonists, combination regimens |
| Deep/histological remission | Most drugs achieve clinical but not histological remission | Treat-to-target strategies; novel endpoints in trials |
| Bowel urgency as therapeutic target | Urgency persists even in clinical remission in ~4% of events | Emerging PRO endpoints in trials (upadacitinib, mirikizumab) |
| Oral advanced therapies | Most advanced biologics are injectable | JAK inhibitors, S1PR modulators, oral IL-23R (icotrokinra) |
| Pediatric UC | Limited approved options for children | Multiple Phase 3 pediatric extensions underway |
| UC + obesity/metabolic comorbidity | No approved combination strategy | COMMIT-UC (mirikizumab + tirzepatide) |
| Steroid-refractory acute severe UC | High colectomy rates | RESCUE-UC trial ongoing |
| Microbiome-based therapy | FMT approved in Canada only; LBPs emerging | HZBio-2 Phase 3; MGT-001; SK08 |
9. Key Company Competitive Profiles
AbbVie — Dominant Dual-Mechanism Leader
- Holds the broadest approved UC portfolio: upadacitinib (JAK1i) + risankizumab (IL-23p19i)
- REVAMP trial directly compares risankizumab vs. vedolizumab — a head-to-head designed to establish superiority
- Pipeline: lutikizumab (IL-1α/β bispecific, Phase 3), LANCL agonist omilancor (acquired via Landos)
- Strategic position: Maximizing revenue through indication expansion and head-to-head differentiation
Eli Lilly — IL-23 Specialist with Combination Innovation
- Mirikizumab (Omvoh) approved March 2023 for UC — first IL-23p19i specifically approved for UC
- COMMIT-UC trial (mirikizumab + tirzepatide) is the first combination IBD+metabolic trial — innovative but high-risk
- Strategic position: Differentiation through combination strategies and comorbidity focus
J&J (Janssen) — Broadest Mechanism Coverage
- Established with infliximab, golimumab (anti-TNF), and vedolizumab (anti-integrin)
- Icotrokinra (oral IL-23R cyclic peptide) approved March 2026 — a genuine first-in-class oral IL-23R antagonist
- Afimkibart (RO7790121) in Phase 3 AMETRINE program (adult + pediatric)
- Strategic position: Widest mechanism breadth; oral IL-23R a key differentiator vs. injectable competition
Roche/Chugai — TL1A Bet
- Duvakitug (anti-TL1A) in Phase 3 SUNSCAPE-1/2 — induction and maintenance
- Chugai in-licensed RG6631 (anti-TL1A) for Japan/Asia
- Strategic position: Concentrated TL1A bet; success depends on Phase 3 readout differentiation
Pfizer — S1PR + TL1A Bispecific Option
- Etrasimod (Velsipity) approved October 2023 — S1PR1/4/5 agonist
- Roche option on Pfizer’s p40/TL1A bispecific antibody
- Strategic position: Oral convenience play + next-gen bispecific optionality
Gilead — JAK1 Niche
- Filgotinib (Jyseleca) approved EU/Japan but not US (FDA rejection in RA) — UC approval in EU
- Pediatric UC trial (Galapeduca) ongoing
- Strategic position: Limited to ex-US markets; pediatric expansion as growth vector
If you want to generate similar competitive landscape reports for other targets, drugs, or companies, AI tools like Eureka LS can significantly reduce the time and effort required, while improving consistency and depth of analysis.
10. Risks & Strategic Implications
Key risks in the competitive landscape:
- Mechanism crowding in IL-23/JAK space: Multiple IL-23p19 inhibitors and JAK1 inhibitors compete for the same patients; differentiation requires head-to-head data or superior safety profiles
- JAK inhibitor class safety: Black box warnings (cardiovascular, malignancy, thrombosis) limit use in older/comorbid patients; S1P modulators and IL-23 inhibitors benefit from this
- Biosimilar erosion: Anti-TNF biosimilars (adalimumab, infliximab) are aggressively eroding the legacy biologic segment; vedolizumab biosimilars entering market
- TL1A validation uncertainty: Both duvakitug and tulisokibart are in Phase 3 but the target’s clinical validation in UC remains pending readout
- Regulatory divergence: Filgotinib’s US/EU split illustrates the risk of geography-specific regulatory outcomes affecting commercial reach
Emerging opportunity signals:
- Oral advanced therapies (JAK inhibitors, S1PR modulators, oral IL-23R icotrokinra) are gaining preference over injectables among patients
- Pediatric UC is underserved with multiple Phase 3 programs now addressing this gap
- Gut microbiome-based therapies (FMT, LBPs) represent a nascent but growing segment, particularly in combination strategies
- LANCL pathway (omilancor) and TL1A represent genuinely novel mechanisms that could address biologic-refractory patients
Data sourced from Patsnap Synapse database as of May 2026. Pipeline status reflects current registration data; Phase 3 counts (74 active trials) may include trials with recent status changes. Patent publication lag (~18 months) may affect completeness of recently filed IP. This report covers competitive intelligence only and does not constitute medical or investment advice.
Turn Complex Data into Decision-Ready Insights
Use Eureka LS to generate competitive intelligence reports across any target, drug, or company.
- ✔ Domain-specific research Q&A
- ✔ Patent & literature analysis (2 files per upload)
- ✔ Lead compound analysis with SAR extraction (5 runs)
- ✔ 2 AI-powered Pulse briefs for early signals
